Keywords: SAT; System auxiliary transformer; OPC; Open phase condition; OPD; Open phase detection; CT; Current transformer; PT; Potential transformer; DFR; Digital fault recorder; EMTP; Electromagnetic transient programs; UMEC; Unified magnetic equivalent circuit;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA
Keywords: Combination therapy; COPD; Inhaled corticosteroids; Long-acting bronchodilators; LAMA/LABA; Fixed-dose dual bronchodilators; CDS; Chronic Disease Score; CI; confidence interval; COPD; chronic obstructive pulmonary disease; ER; emergency room; FDC; fixed-d
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
Keywords: Long-acting muscarinic antagonist; Inhaled corticosteroid; Long-acting beta2 agonist; Bronchodilation; AE; adverse event; ASE; all subjects enrolled; CAT; COPD Assessment Test; CI; confidence interval; COPD; chronic obstructive pulmonary disease; FEV1; fo
A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma
Keywords: Asthma; Fixed-dose combination; Muscarinic antagonist; Inhaled corticosteroid; Trough FEV1; Ae; amount of dose excreted unchanged in urine; AE; adverse event; ALT; alanine aminotransferase; AUC; area under the curve; BID; twice daily; bpm; beats per minut
A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD
Keywords: AE; adverse event; FSC; fluticasone propionate/salmeterol; ICS; inhaled corticosteroid; LABA; long-acting Ã2-agonist; LAMA; long-acting muscarinic antagonist; MCID; minimal clinically important difference; NNTB; number needed to treat for benefit; SAE; s
Efficacy and safety of umeclidinium/vilanterol 62.5/25Â mcg and tiotropium 18Â mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
Keywords: Long-acting bronchodilator; Umeclidinium; Vilanterol; AE; adverse event; CI; confidence interval; COPD; chronic obstructive pulmonary disease; DPI; Dry powder inhaler; FEV1; forced expiratory volume in one second; FP; fluticasone propionate; FVC; forced v